← Mechanisms of action
CD40-CD40L
PROTEIN-PROTEIN INTERACTIONHomo sapiens
Linked proteins
Drugs acting on this target (18)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| mp0317 | Agonist | experimental | Recombinant protein | CD40-CD40L agonist |
| ro7300490 | Agonist | experimental | Recombinant protein | CD40-CD40L agonist |
| gm.cd40l | Immunity, active | experimental | Vaccine | CD40-CD40L immunity, active |
| gm.cd40l cells | Immunity, active | experimental | Vaccine | CD40-CD40L immunity, active |
| gm.cd40l vaccine | Immunity, active | experimental | Vaccine | CD40-CD40L immunity, active |
| gm.cd40l.ccl21 | Immunity, active | experimental | Vaccine | CD40-CD40L immunity, active |
| il-2 secreting and hcl4ol-expressing autologous b-cll cells | Immunity, passive | experimental | Cell therapy | CD40-CD40L immunity, passive |
| il-2-secreting cd40l-expressing autologous b-cll cells | Immunity, passive | experimental | Vaccine | CD40-CD40L immunity, passive |
| tcrx t cell | Immunity, passive | experimental | Cell therapy | CD40-CD40L immunity, passive |
| BNT314 | Inhibitor | experimental | mAb | CD40-CD40L inhibitor |
| frexalimab | Inhibitor | experimental | mAb | CD40-CD40L inhibitor |
| ibi355 | Inhibitor | experimental | mAb | CD40-CD40L inhibitor |
| ng-350a | Inhibitor | experimental | Gene therapy | CD40-CD40L inhibitor |
| shr-7367 | Inhibitor | experimental | mAb | CD40-CD40L inhibitor |
| tnx-1500 | Inhibitor | experimental | mAb | CD40-CD40L inhibitor |
| adcd40l | Supplementation | experimental | Gene therapy | CD40-CD40L supplementation |
| adcucd40l | Supplementation | experimental | Gene therapy | CD40-CD40L supplementation |
| cd40 gene transfer | Supplementation | experimental | Gene therapy | CD40-CD40L supplementation |